EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring membranous NECTIN‐4 expression patterns and enfortumab vedotin response in prostate cancer

Richard Weiten iD, Marit Bernhardt, Max Niemann, Glen Kristiansen, Viktor Grünwald, Manuel Ritter, Michael Hölzel, Markus Eckstein, Abdullah Alajati, Niklas Klümper, Philipp Krausewitz

Journal of Cellular and Molecular Medicine · 2024

DOI: 10.1111/jcmm.18572 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Richard Weiten und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Cell Adhesion Molecules, Antibodies, Monoclonal, Prostatic Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody‐drug conjugates (ADCs) represent a novel type of targeted cancer therapy combining the specificity of monoclonal antibodies with the cytotoxicity of conventional chemotherapy. Recently, ADCs have demonstrated practice‐changing efficacy across diverse solid cancers. The anti‐NECTIN‐4 ADC enfortumab vedotin (EV) has just been approved for patients with urothelial cancer and is currently under investigation for patients with castration‐resistant prostate cancer (CRPC e.g. Phase II ENCORE trial). Our objective was to evaluate the efficacy of EV in established prostate cancer (PCa) cell lines and to examine the membranous NECTIN‐4 expression in primary tumours (PRIM) and distant metastases (MET). NECTIN‐4 was heterogeneously expressed in the panel of PCa cell lines. EV led to growth inhibition in NECTIN‐4 expressing PCa cells (22Rv1 and LNCaP), whereas the NECTIN‐4‐negative PC‐3 cells were significantly less responsive to EV, emphasizing the dependence of EV response on its target expression. Immunohistochemical staining revealed moderate membranous NECTIN‐4 expression only in a small subgroup of CRPC patients with lung and peritoneal MET [ n = 3/22 with H‐score ≥100, median H‐score 140 (IQR 130–150)], while 100% of PRIM ( n = 48/48) and 86.4% of common MET sites ( n = 19/22), including lymph node, bone and liver MET, were NECTIN‐4 negative. In summary, EV may be effective in NECTIN‐4‐positive PCa. However, our findings demonstrate that the tumoural NECTIN‐4 expression is predominantly low in metastatic PCa, which suggests that EV may only be effective in a biomarker‐stratified subgroup.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell Adhesion MoleculesAntibodies, MonoclonalProstatic NeoplasmsHumansMaleCell Line, TumorGene Expression Regulation, NeoplasticImmunoconjugatesProstatic Neoplasms, Castration-ResistantCell ProliferationNectins

Stichwörter der Autor:innen

NECTIN‐4antibody‐drug conjugatesenfortumab vedotinmCRPCprostate cancer

Substanzen

NECTIN4 protein, humanCell Adhesion MoleculesAntibodies, Monoclonalenfortumab vedotinImmunoconjugatesNectins

Autor:innen und Institutionen

  • Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany.
  • Department of Urology Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Koln, Germany.
  • Institute of Pathology, University Hospital Bonn, Bonn, Germany.
  • Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, Essen University Hospital, Essen, Germany.
  • Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany.
  • Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

ORCID-Profile: Richard Weiten

Zitieren

APA

Weiten, R., Bernhardt, M., Niemann, M., Kristiansen, G., Grünwald, V., Ritter, M., Hölzel, M., Eckstein, M., Alajati, A., Klümper, N., & Krausewitz, P. (2024). Exploring membranous NECTIN‐4 expression patterns and enfortumab vedotin response in prostate cancer. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18572

Vancouver

Weiten R, Bernhardt M, Niemann M, Kristiansen G, Grünwald V, Ritter M, et al. Exploring membranous NECTIN‐4 expression patterns and enfortumab vedotin response in prostate cancer. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18572

BibTeX
@article{Weiten2024,
  author = {Weiten, Richard and Bernhardt, Marit and Niemann, Max and Kristiansen, Glen and Grünwald, Viktor and Ritter, Manuel and Hölzel, Michael and Eckstein, Markus and Alajati, Abdullah and Klümper, Niklas and Krausewitz, Philipp},
  title = {Exploring membranous NECTIN‐4 expression patterns and enfortumab vedotin response in prostate cancer},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  doi = {10.1111/jcmm.18572}
}
Kostenlos starten →